Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by SanFrancisco99on May 12, 2012 4:21pm
398 Views
Post# 19902848

Still Optomistic After All These Years

Still Optomistic After All These Years

I've bought a few more shares here and there over the past several weeks - putting my money where my mouth is.  My general sense of faith in this company remains unshaken.  The net-net is that the science seems to be still very strong & impressive after all these years.  Actually, my confidence in that has only increased over time.

Let's hope they have their business development/sales act in order.  Let's also hope that they are right in saying that ASSURE is on-track as of the latest schedule.  Finally, let's also hope that SUSTAIN shows the kind of results that we expect (consistent (or increasingly better over time) bio marker readings, a downward trend to longer-term liver ALTs, etc.). 

As always, there are plenty of potential "gotchas" with this stock - it's a high-risk investment for sure.  But the potential for a deal is always ever-present.  I think it is becomming a higher chance likelihood with each passing month.

There are those who think we will have to wait a long time for that potential deal.  I'm not so sure.  As I have written, the concept of freedom of contract in the law is an amazing thing:  Contracts can be drafted to cover just about any potential concern or contingency.  Thus, someone might come along who wants to take this deal off the table before their competitors do.

I think it's becomming much more "ripe" in that sense.  The need for a next-generation cardio protective drug is greater now than ever.  The potential competitors to RVX-208 are rapidly becomming less of a threat.  People in Western Countries are still eating a whole lot of Big Macs, french fries, and ice cream.  Can you imagine how crazy people might go over this particular drug if it works as it is believed to work?  It has the potential of becomming something that hits popular culture and everyday conversation.  It really does have that potential....

When and if a deal happens, I think we won't get a lot of warning signals beforehand.  Time to be prepared for that particular contingency. 

 

 

 

Bullboard Posts